Dec. 22, 2014 - Amarantus anticipates reporting final top-line data of its LP-002 clinical study to assess LymPro's predictive value in diagnosing mild to severe Alzheimer's disease patients by the end of 2014 .

4M shares changed hands so far this morning. Those that have sold may have forgotten there is more news within the next seven days.

http://ir.amarantus.com/company-news/detail/1...cal-trials